Sample | Normal | BPH | PCA | Misclassified rate |
---|---|---|---|---|

A. Training set | ||||

HM (N = 82) | 78 (95.12%) | 0 (0.00%) | 4 (4.88%) | 4 (4.88%) |

BPH (N = 77) | 0 (0.00%) | 72 (93.51%) | 5 (6.49%) | 5 (6.49%) |

PCA stage T_{1}, T_{2} (N = 84) | 2 (2.38%) | 0 (0.00%) | 82 (97.61%) | 2 (2.38%) |

PCA, stage T_{3}, T_{4} (N = 83) | 2 (2.40%) | 0 (0.00%) | 81 (97.59%) | 2 (2.41%) |

Total no. of samples (N = 326) | 13 (3.99%) |

Sample | Normal | BPH | PCA | Misclassified rate |
---|---|---|---|---|

B. Test set | ||||

HM (N = 15) | 15 (100.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |

BPH (N = 15) | 0 (0.00%) | 14 (93.33%) | 1 (6.67%) | 1 (6.67%) |

PCA, stage T_{1}, T_{2} (N = 15) | 3 (6.67%) | 0 (0.00%) | 12 (80.00%) | 3 (20.00%) |

PCA, stage T_{3}, T_{4} (N = 15) | 1 (6.67%) | 1 (6.67%) | 13 (86.67%) | 2 (13.33%) |

Total no. of samples (N = 60) | 6 (10.00%) |

Disease/nondisease | Percent positive (no. positive/no. tested) | |||||
---|---|---|---|---|---|---|

PCA/HM | PCA/BPH | PCA/(BPH/HM) | BPH/HM | BPH/T1,T2 | Ti,T2/T3,T4 | |

C. Differentiation of prostate disease from nondisease in the blinded test set | ||||||

Sensitivity | 83 (25/30) | 83 (25/30) | 83 (25/30) | 93 (14/15) | 93 (14/15) | 80 (12/15) |

Specificity | 100 (15/15) | 93 (14/15) | 97 (29/30) | 100 (15/15) | 80 (12/15) | 87 (13/15) |